InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (1 ops.)
Insider track record
Board DirectorDisclosed buys
4
Disclosed sells
1
T+90 hit rate
0%
T+90 mean return
-24.4%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Milne George M Jr, Director. Director active across 4 companies, notably CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Aggregated, 11 reports have been logged. Breakdown: 4 buys · 1 sell. Total volume traded: €1.9m. History available since 7 May 2021. The latest transaction was disclosed on 12 January 2026 (Don). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Milne George M Jr
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations11 total
17,780 shares0Common StockSEC:0001193125-26-012921:0
27,910 shares0Common StockSEC:0000950170-25-009913:0
100,000 shares@ US$2.1989.6% of flowCommon StockSEC:0000950170-24-104186:0
Canonical exit: 2 Dec 2024 (T+90)
9,100 shares0Common StockSEC:0000950170-24-008347:0
94,350 shares0Common StockSEC:0000950170-24-005437:0
8,733 sharesCommon StockSEC:0001600620-23-000019:0
33,084 shares@ US$31.855347.9% of flowCommon StockSEC:0000899243-23-009179:0
20,000 shares@ US$8.914277.4% of flowCommon StockSEC:0001628280-23-006533:0
Canonical exit: 31 May 2023 (T+90)
5,000 shares@ US$10.820.0023% mcap100.0% of flowCommon StockSEC:0001628280-22-005381:0
Canonical exit: 2 Jun 2022 (T+90)
26,315 shares@ US$19.0027.0% of flowCommon StockSEC:0000899243-22-001521:0
Canonical exit: 6 Apr 2022 (T+90)
355 shares0Common StockSEC:0001127602-21-016113:0
11 of 11 declarations
About Milne George M Jr
George M. Milne Jr. is a Director at Charles River Laboratories International, Inc. and Amylyx Pharmaceuticals, Inc. In this role, he participates in the governance and strategic direction of these companies. George brings his expertise to help guide decisions that support the mission and objectives of Charles River and Amylyx.
